HLS Therapeutics Inc.

HLS

CA40390B1094

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 15:59:17 2024-05-22 EDT			5-day change	1st Jan Change
3.85 ^CAD	-1.28%		-3.02%	-2.53%

05-09	Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
05-09	HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	MT

HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024

May 09, 2024 at 06:30 am

HLS Therapeutics Inc. updated consolidated revenue guidance for the full year 2024. for the year, the company is lowering its full year consolidated revenue guidance to a range of $60 million - $62 million from $63.5 million -$66.5 million.

Latest news about HLS Therapeutics Inc.

Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	05-09	MT
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
HLS Therapeutics Brief: Q1 2024 revenue was US$12.5 million, Adjusted EBITDA was $2.7 million and cash from operations was $0.8 million	05-09	MT
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024	05-09	CI
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	04-08	CI
Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024	03-14
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update	03-14	MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022	03-14	MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million	03-14	MT
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024	03-14	CI
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan	02-06	MT
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	02-06	MT
HLS Therapeutics Inc. Announces CFO Changes	12-18	CI
HLS Therapeutics Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	12-18	MT
HLS Therapeutics Brief: Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	12-18	MT
HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo	11-14	MT
HLS Therapeutics Brief: Says New REDUCE-IT Analyses Show Vascepa (Icosapent Ethyl) Associated with 29% Relative Risk Reduction Vs Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline	11-14	MT
HLS Therapeutics Inc. Announces Results from New REDUCE-IT Analyses	11-14	CI
HLS Therapeutics Inc.'s Equity Buyback announced on November 10, 2022, has expired.	11-12	CI
HLS Therapeutics Downgraded to Hold at Stifel GMP on Revenue Concerns; Price Target Cut to C$5.00	11-10	MT
HLS Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022.	11-09	CI

Chart HLS Therapeutics Inc.

Duration

Period

More charts

Company Profile

HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.

Sector

Pharmaceuticals

Calendar

2024-06-07 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for HLS Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.816 USD

Average target price

3.885 USD

Spread / Average Target

+37.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
HLS THERAPEUTICS INC.	-2.53%	89.59M
CARDINAL HEALTH, INC.	-4.44%	23.46B
SINOPHARM GROUP CO. LTD.	+4.89%	8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+7.83%	8.35B
HUADONG MEDICINE CO., LTD	-21.35%	7.88B
H. LUNDBECK A/S	+15.32%	5.21B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+10.84%	4.09B
EBOS GROUP LIMITED	-1.97%	4.11B
GALENICA AG	-0.89%	3.87B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+20.72%	3.6B

Pharmaceuticals Wholesale